ZVRA
VENTE TOTALE: 12 300 titres (~138 377,46 $ US)
- Insiders
- Watton Corey Michael
- Total bought
- —
- Total sold
- $138,377
- Last activity
- 2026-08-10
- Last synced
-
2026-08-16 09:56:14
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Neutral signal Scored 2026-08-13
ZVRA shows genuine operational improvement with strong margin recovery and a solid liquidity score of 75, but persistent negative operating cash flow and a weak interest coverage ratio undermine the fundamental thesis.
The first sentence of the analysis written for ZVRA on 2026-08-13 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 84.5% | 68.6% | 89.3% | 97.8% | 92.8% | |
| Ebit Margin | 88.9% | -350.6% | -162.2% | -260.5% | -28.4% | |
| Ebitda Margin | 92.7% | -323.6% | -158.6% | -251.2% | -27.5% | |
| Operating Profit Margin | -4.0% | -368.5% | -180.6% | -418.9% | 27.0% | |
| Pretax Profit Margin | 81.4% | -381.8% | -167.7% | -263.8% | -29.7% | |
| Continuous Operations Profit Margin | 78.2% | -446.9% | -167.7% | -263.5% | -29.9% | |
| Net Profit Margin | 78.2% | -446.9% | -167.7% | -263.5% | -29.9% | |
| Bottom Line Profit Margin | 72.9% | -446.9% | -167.7% | -263.5% | -219.5% | |
| Current Ratio | 5.678 | 2.525 | 1.179 | 7.721 | 27.200 | |
| Quick Ratio | 5.634 | 2.468 | 0.853 | 7.721 | 27.200 | |
| Solvency Ratio | 0.671 | -0.716 | -0.408 | -0.642 | -1.425 | |
| Cash Ratio | 1.589 | 0.992 | 0.584 | 5.445 | 26.559 | |
| Price To Earnings Ratio | 6.400 | -3.658 | -5.038 | -5.885 | -4.128 | |
| Price To Earnings Growth Ratio | -0.040 | -0.049 | -0.076 | 0.093 | 0.120 | |
| Forward Price To Earnings Growth Ratio | -0.040 | -0.049 | -0.076 | 0.093 | 0.120 | |
| Price To Earnings Diluted Ratio | 6.637 | -3.658 | -5.038 | -5.885 | -4.128 | |
| Price To Earnings Diluted Growth Ratio | -0.042 | -0.049 | -0.076 | 0.093 | 0.120 | |
| Price To Book Ratio | 3.204 | 9.725 | 3.754 | 2.107 | 2.040 | |
| Price To Sales Ratio | 4.655 | 16.336 | 8.456 | 15.580 | 9.049 | |
| Price To Free Cash Flow Ratio | -203.695 | -5.537 | -6.864 | -8.416 | 25.081 | |
| Price To Operating Cash Flow Ratio | -310.131 | -5.537 | -6.925 | -8.458 | 24.836 | |
| Debt To Assets Ratio | 0.222 | 0.339 | 0.254 | 0.163 | 0.012 | |
| Debt To Equity Ratio | 0.409 | 1.520 | 0.707 | 0.250 | 0.013 | |
| Debt To Capital Ratio | 0.290 | 0.603 | 0.414 | 0.200 | 0.012 | |
| Long Term Debt To Capital Ratio | 0.286 | 0.600 | 0.076 | 0.146 | 0.000 | |
| Financial Leverage Ratio | 1.841 | 4.491 | 2.786 | 1.535 | 1.046 | |
| Working Capital Turnover Ratio | 0.903 | 0.725 | 0.584 | 0.106 | 0.513 | |
| Operating Cash Flow Ratio | -0.041 | -2.045 | -0.455 | -1.557 | 2.468 | |
| Operating Cash Flow Sales Ratio | -0.015 | -2.950 | -1.221 | -1.842 | 0.364 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.523 | 1.000 | 1.009 | 1.005 | 0.990 | |
| Debt Service Coverage Ratio | 11.942 | -12.484 | -1.111 | -5.109 | -21.069 | |
| Interest Coverage Ratio | -0.531 | -11.836 | -33.047 | -127.060 | 20.556 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | -0.890 | -4.021 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -0.025 | -1.155 | -0.766 | -0.997 | 6.488 | |
| Capital Expenditure Coverage Ratio | -1.914 | 0.000 | -113.294 | -201.258 | 102.343 | |
| Dividend Paid And Capex Coverage Ratio | -1.914 | 0.000 | -113.294 | -201.258 | 102.343 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 5.029 | -5.396 | -5.350 | -4.373 | -18.830 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 84.5% | ▲15.9% | ▼-2.1% |
| Ebit Margin | 88.9% | ▲439.5% | ▲231.5% |
| Ebitda Margin | 92.7% | ▲416.3% | ▲226.3% |
| Operating Profit Margin | -4.0% | ▲364.5% | ▲185.0% |
| Pretax Profit Margin | 81.4% | ▲463.2% | ▲233.7% |
| Continuous Operations Profit Margin | 78.2% | ▲525.0% | ▲244.1% |
| Net Profit Margin | 78.2% | ▲525.0% | ▲244.1% |
| Bottom Line Profit Margin | 72.9% | ▲519.7% | ▲277.8% |
| Current Ratio | 5.678 | ▲3.152 | ▼-3.183 |
| Quick Ratio | 5.633 | ▲3.166 | ▼-3.142 |
| Solvency Ratio | 0.671 | ▲1.387 | ▲1.175 |
| Cash Ratio | 1.589 | ▲0.597 | ▼-5.445 |
| Price To Earnings Ratio | 6.400 | ▲10.058 | ▲8.862 |
| Price To Earnings Growth Ratio | -0.040 | ▲0.009 | ▼-0.050 |
| Forward Price To Earnings Growth Ratio | -0.040 | ▲0.009 | ▼-0.050 |
| Price To Earnings Diluted Ratio | 6.637 | ▲10.295 | ▲9.051 |
| Price To Earnings Diluted Growth Ratio | -0.042 | ▲0.007 | ▼-0.051 |
| Price To Book Ratio | 3.204 | ▼-6.520 | ▼-0.962 |
| Price To Sales Ratio | 4.655 | ▼-11.682 | ▼-6.160 |
| Price To Free Cash Flow Ratio | -203.695 | ▼-198.158 | ▼-163.809 |
| Price To Operating Cash Flow Ratio | -310.131 | ▼-304.594 | ▼-248.888 |
| Debt To Assets Ratio | 0.222 | ▼-0.117 | ▲0.024 |
| Debt To Equity Ratio | 0.409 | ▼-1.111 | ▼-0.171 |
| Debt To Capital Ratio | 0.290 | ▼-0.313 | ▼-0.014 |
| Long Term Debt To Capital Ratio | 0.286 | ▼-0.314 | ▲0.065 |
| Financial Leverage Ratio | 1.841 | ▼-2.650 | ▼-0.499 |
| Working Capital Turnover Ratio | 0.903 | ▲0.179 | ▲0.337 |
| Operating Cash Flow Ratio | -0.041 | ▲2.004 | ▲0.285 |
| Operating Cash Flow Sales Ratio | -0.015 | ▲2.935 | ▲1.118 |
| Free Cash Flow Operating Cash Flow Ratio | 1.522 | ▲0.522 | ▲0.417 |
| Debt Service Coverage Ratio | 11.942 | ▲24.426 | ▲17.508 |
| Interest Coverage Ratio | -0.531 | ▲11.305 | ▲29.853 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | ▲0.982 |
| Operating Cash Flow Coverage Ratio | -0.025 | ▲1.130 | ▼-0.734 |
| Capital Expenditure Coverage Ratio | -1.914 | ▼-1.914 | ▲40.911 |
| Dividend Paid And Capex Coverage Ratio | -1.914 | ▼-1.914 | ▲40.911 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 5.029 | ▲10.425 | ▲10.813 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $495.6M | $385.7M | $232.2M | $158.3M | $259.3M | |
| Enterprise value | $496.4M | $412.2M | $232.9M | $111.6M | $148.5M | |
| EV / Sales | 4.66x | 17.46x | 8.48x | 10.98x | 5.18x | |
| EV / Op. cash flow | -310.63x | -5.92x | -6.95x | -5.96x | 14.23x | |
| EV / Free cash flow | -204.02x | -5.92x | -6.88x | -5.93x | 14.37x | |
| EV / EBITDA | 5.03x | -5.40x | -5.35x | -4.37x | -18.83x | |
| Net debt / EBITDA | 0.01x | -0.35x | -0.02x | 1.83x | 14.04x | |
| Current ratio | 5.68x | 2.52x | 1.18x | 7.72x | 27.20x | |
| Income quality | -0.02x | 0.66x | 0.73x | 0.70x | -1.22x | |
| Graham number | $10 | — | — | — | — | |
| Graham net-net | $1 | -$1 | -$0 | $1 | $4 | |
| Tax burden | 96.0% | 117.1% | 100.0% | 99.9% | 100.4% | |
| Interest burden | 91.6% | 108.9% | 103.4% | 101.3% | 104.6% | |
| Working capital | $183.7M | $52.0M | $13.2M | $80.8M | $110.8M | |
| Invested capital | $196.6M | $126.7M | $88.7M | $82.6M | $112.9M | |
| Return on assets | 29.2% | -59.2% | -26.7% | -23.2% | -6.4% | |
| Operating ROA | -1.8% | -49.7% | -34.5% | -34.3% | 10.7% | |
| Return on tangible assets | 30.4% | -101.0% | -46.8% | -23.2% | -6.4% | |
| Return on equity | 53.8% | -266.0% | -74.4% | -35.6% | -6.7% | |
| Return on invested capital | -1.7% | -60.2% | -36.2% | -39.2% | 6.0% | |
| Return on capital employed | -1.7% | -60.4% | -50.3% | -41.2% | 6.0% | |
| Earnings yield | 16.8% | -27.4% | -19.8% | -16.9% | -3.3% | |
| Free cash flow yield | -0.5% | -18.1% | -14.6% | -11.9% | 4.0% | |
| Capex / Op. cash flow | -52.3% | 0.0% | -0.9% | -0.5% | 1.0% | |
| Capex / Depreciation | 20.6% | 0.0% | 29.4% | 9.9% | 39.7% | |
| Capex / Sales | 0.8% | 0.0% | 1.1% | 0.9% | 0.4% | |
| SG&A / Sales | 72.9% | 232.4% | 127.8% | 148.0% | 30.4% | |
| R&D / Sales | 12.0% | 178.3% | 145.0% | 194.9% | 35.5% | |
| Stock comp / Sales | 11.9% | 63.1% | 21.7% | 0.0% | 8.5% | |
| Intangibles / Total assets | 3.9% | 41.4% | 42.9% | 0.0% | 0.0% | |
| Days sales outstanding | 80d | 162d | 231d | 298d | 19d | |
| Days payables outstanding | 55d | 643d | 1734d | 5937d | 91d | |
| Operating cycle | 118d | 259d | 3216d | 298d | 19d | |
| Cash conversion cycle | 63d | -384d | 1482d | -5639d | -72d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+28.5%EV / Sales ▼-73.3%EV / EBITDA ▲+193.2%EV / Op. cash flow ▼-304.714Earnings yield ▲+0.441
Profitability
Return on equity ▲+3.198Return on assets ▲+0.885Return on invested capital ▲+0.586Return on capital employed ▲+0.587Operating ROA ▲+0.478Income quality ▼-0.679Tax burden ▼-0.210
Efficiency
Days sales outstanding ▼-82.718Days payables outstanding ▼-588.561Operating cycle ▼-141.131Cash conversion cycle ▲+447.430Capex / Sales n/aR&D / Sales ▼-1.663
Balance-sheet strength
Current ratio ▲+3.152Net debt / EBITDA ▲+0.355Working capital ▲+131768000.000Invested capital ▲+69884000.000Intangibles / Total assets ▼-0.375
Change over 5 years
Valuation
Market cap ▲+91.2%EV / Sales ▼-10.1%EV / EBITDA ▲+126.7%EV / Op. cash flow ▼-324.860Earnings yield ▲+0.201
Profitability
Return on equity ▲+0.605Return on assets ▲+0.357Return on invested capital ▼-0.076Return on capital employed ▼-0.077Operating ROA ▼-0.126Income quality ▲+1.201Tax burden ▼-0.044
Efficiency
Days sales outstanding ▲+60.266Days payables outstanding ▼-36.595Operating cycle ▲+98.799Cash conversion cycle ▲+135.395Capex / Sales ▲+0.004R&D / Sales ▼-0.235
Balance-sheet strength
Current ratio ▼-21.522Net debt / EBITDA ▼-14.031Working capital ▲+72904000.000Invested capital ▲+83702000.000Intangibles / Total assets n/a
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-08-13 INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA NEW YORK, Aug. 13, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zevra Therapeutics, Inc. ("Zevra" or the "Company") (NASDAQ: ZVRA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 2026-08-12 Dimensional Fund Advisors LP Acquires 400,336 Shares of Zevra Therapeutics, Inc. $ZVRA Dimensional Fund Advisors LP boosted its holdings in Zevra Therapeutics, Inc. (NASDAQ: ZVRA) by 259.2% in the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 554,802 shares of the company''s stock after buying an additional 400,336 shares during the quarter. Dimensional Fund Advisors
- 2026-08-11 INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA NEW YORK, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zevra Therapeutics, Inc. (“Zevra” or the “Company”) (NASDAQ: ZVRA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
- 2026-08-06 INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA NEW YORK, Aug. 6, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zevra Therapeutics, Inc. ("Zevra" or the "Company") (NASDAQ: ZVRA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 2026-08-06 Zevra Therapeutics Q2 Earnings Call Highlights Zevra Therapeutics NASDAQ: ZVRA reported second-quarter 2026 net revenue of $39.7 million, up 53% from $25.9 million a year earlier, driven primarily by U.S. sales of its Niemann-Pick disease type C treatment MIPLYFFA.
- 2026-08-05 Zevra Therapeutics, Inc. (ZVRA) Q2 2026 Earnings Call Transcript Zevra Therapeutics, Inc. (ZVRA) Q2 2026 Earnings Call Transcript
- 2026-08-05 Zevra Therapeutics (ZVRA) Q2 Earnings and Revenues Surpass Estimates Zevra Therapeutics (ZVRA) came out with quarterly earnings of $0.25 per share, beating the Zacks Consensus Estimate of $0.08 per share. This compares to earnings of $1.21 per share a year ago.
- 2026-08-05 Zevra Reports Second Quarter 2026 Financial Results and Corporate Update $39.7 million net revenue for Q2 2026, driven by $30.2 million in revenue from MIPLYFFA 53% increase in total net revenue over Q2 2025 Operational execution fueled strong cash position of $260.2 million Company to host conference call and webcast TODAY, August 5, 2026 , at 4:30 p.m. ET BOSTON, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today reported its financial results for the second quarter ended June 30, 2026.
- 2026-08-04 INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zevra Therapeutics, Inc. (“Zevra” or the “Company”) (NASDAQ: ZVRA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
- 2026-08-04 Zevra Therapeutics to Present at the Canaccord Genuity Annual Growth Conference BOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced that members of Zevra''s executive leadership team will present at the Canaccord Genuity 46th Annual Growth Conference in Boston, MA on Tuesday, August 11, 2026, at 11:00 a.m. ET. Additionally, management will be available for one-on-one meetings with registered conference attendees.